蛋白酶体抑制剂 (Proteasome inhibitors)具有独特的抗肿瘤机制,硼替佐米(Bortezomib)是第一个进入临床试验的 蛋白酶体抑制剂 ,用于多发性骨髓瘤的治疗。
基于31个网页-相关网页
波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。
Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.
目的:研究泛素蛋白酶体抑制剂对胃癌细胞增殖和凋亡的影响。
AIM: to investigate effects of ubiquitin-proteasome inhibitor on proliferation and apoptosis of gastric carcinoma cells.
蛋白酶体抑制剂可选择性地促进肿瘤细胞凋亡,逆转多药耐药。
Proteasome inhibitors can selectively promote the apoptosis of tumor cells and overcome MDR.
应用推荐